The bile acid receptor FXR is a key regulator of hepatic defense mechanisms against bile acids. A comprehensive study addressing the role of FXR in the coordinated regulation of adaptive mechanisms including biosynthesis, metabolism and alternative export together with their functional significance is lacking. We therefore fed FXR knockout mice (FXR -/-
INTRODUCTION
Bile acids are potentially hepatotoxic and their intrahepatic accumulation in cholestasis causes liver injury ultimately leading to liver fibrosis and cirrhosis (11).
Therefore, bile acid homeostasis needs to be tightly regulated (3, 7, 34, 35) . The bile acid receptor farnesoid X receptor (FXR, NR1H4) plays a critical role in the transcriptional regulation of various steps in bile acid homeostasis (7) and loss of FXR leads to increased susceptibility to bile acid-induced liver injury (26,48).
Bile acid-induced liver damage may be counteracted by a coordinated reduction of basolateral bile acid uptake, decreased bile acid synthesis, and induction of bile acid metabolism / detoxification followed by alternative basolateral bile acid secretion (40). Bile acid detoxification can occur via phase I hydroxylation mediated by the cytochrome P450 enzymes Cyp3a11 (2,31,44) (representing the rodent orthologue of human CYP3A4) and potentially Cyp2b10. After alternative secretion via the hepatocyte's basolateral membrane, these water soluble metabolites can be eliminated by the kidney. Alternative hepatic basolateral bile acid excretion during cholestasis is accomplished by induction of multidrug resistance-associated protein Mrp3 (8, 10, 24, 38, 47 ) and Mrp4 (6, 21, 24, 38, 45) . Mrp4 is localized to the basolateral membrane of hepatocytes and to apical membranes of proximal tubular cells in kidney (6, 36 ) and may thus not only assist Mrp3 in alternative hepatic basolateral bile acid export but also renal Mrp2 in urinary bile acid elimination. The role of Mrp5 and Mrp6 in bile acid transport remains elusive but possible since both are localized to basolateral membranes and are expressed in liver and kidney (18, 23, 43) .
In addition to the ABC transporter family, the recently identified organic solute transporter Ost /Ostß represents a novel candidate basolateral bile salt export Zollner et al., Adaptive effects of CA and UDCA G-00490-2005. R1 4 system in the liver. Both subunits (alpha and beta) of this heteromeric transporter are required for transport of various bile acids and their conjugates (4, 25, 42) . In the ileum, where bile acids are taken up by the apical bile salt transporter (Asbt),
Ost /Ostß mediates their basolateral excretion thus contributing to enterohepatic bile acid circulation (4) . Ost /Ostß is also expressed in kidney and -although to lower extents -in liver, where it localizes to the basolateral membrane of hepatocytes and cholangiocytes (29). Although renal localization has not yet been investigated, it is conceivable to hypothesize that Ost /Ostß may be localized to the basolateral membrane as in liver and intestine. It is attractive to speculate that this recently characterized basolateral bile acid exporter may also take part in the adaptive transporter response during cholestasis.
While molecular changes of individual transporters and enzymes in response to bile acid challenge and cholestasis have been reported in the past, a study investigating the role of FXR in orchestrating bile acid effects on adaptive mechanisms together with their functional significance (i.e. bile acid composition) is still lacking. Therefore the aims of this study were (i) to determine, whether potentially toxic cholic acid (CA), a major bile acid accumulating during cholestasis, coordinately regulates expression of bile acid synthesis, detoxification enzymes and alternative basolateral bile acid transporters (including Mrp4-6 and Ost /Ostß) in liver and kidney in the presence and absence of FXR, (ii) to compare these changes to those induced by the therapeutically used ursodeoxycholic acid (UDCA) and (iii) to assess the functional significance of the observed molecular changes by studying bile acid composition. Bile Acid Feeding. To study the effects of CA and UDCA on transporter expression, male mice were fed either a diet supplemented with CA (1%, w/w; Aldrich (Steinheim, Germany)) or UDCA (1%, w/w; kindly provided by the Falk Foundation, Freiburg, Germany) for 7 days (8,37,47). Controls were fed a standard mouse diet. The livers were excised and processed as described (8, 47) . Part of the animals was analyzed in a previous study (47). Green assays without using specific probes were performed for determination of Ost and Ostß mRNA.
MATERIAL AND METHODS

Animals
Preparation of total
Preparation of liver membranes and analysis of Mrp4 protein levels by
Western blotting. Liver and kidney membranes were prepared as described previously (33,39,47). Mrp4 protein levels were determined using a polyclonal antibody against Mrp4 (dilution, 1:1000; kindly provided by Dr. John D Schuetz, St.
Jude's Children's Research Hospital, Memphis, Tennessee) as described (38,39).
Blots were reprobed with an anti-ß-actin antibody (dilution, 1:5000, Sigma) to confirm the specificity of changes in transporter protein levels.
Bile acid measurements. Liver pieces (50-100µg) and serum (50-100 µl) of 3 animals per group were pooled, extracted and analyzed by electrospray-and gas chromatography-mass spectrometry as described previously (38).
Statistical analysis.
In each group 3-5 animals were studied. Data are reported as arithmetic means ± SD. For statistical analysis, one-way analysis of variance (ANOVA) was used with Bonferroni post-testing testing when appropriate. Taken together, the magnitude of Mrp4 induction depends on the amount of bile acid levels and is independent of FXR.
Hepatic and renal Mrp5 and Mrp6 mRNA expression levels were not affected by CA and UDCA feeding.
Baseline Mrp5 mRNA levels were 10 fold higher in kidney than in liver while Taken together, Asbt repression after CA or induction after UDCA feeding in ileum may account for the observed differences in bile acid levels. Since both Mrp5 and Mrp6 are expressed in liver and kidney (23), we speculated that Mrp5 and 6 could possibly contribute to alternative bile acid elimination in cholestasis. While a role for in bile acid transport is questioned by a previous study (17) the role of Mrp5 in bile acid transport is currently under investigation. In the present study, neither CA nor UDCA were able to increase Mrp5 and 6 expression, which makes their involvement in these adaptive excretory pathways less likely.
In summary, we demonstrate FXR-dependent and independent adaptive changes including repression of bile acid synthesis and induction of bile acid hydroxylation and alternative basolateral efflux in response to bile acid challenge ( Figure 5 
